Q2 2011

Filed May 16, 2011 · 10-Q · 46 days after period end · 0001062993-11-002170

Q2 2011 · 10-Q

Revenue—

Net Income

-$1.97M

no prior Q2 2010 on file

EPS Diluted

-$0.08

no prior Q2 2010 on file

Operating Income-$1,947,725—

Operating Cash Flowderived-$588,942—

Same quarter

no prior Q2 2010 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Mar 31, 2011 · filed May 16, 2011 · 46 d after period end

Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR